Dr. Kathryn M Ferguson's lab at Yale University focuses on understanding how the environment of cells, specifically the membranes they are part of, affects the behavior and structure of integral membrane proteins (IMPs). This research is critical because many drugs target these proteins, but we often don't fully understand how they work. By using innovative technologies and interdisciplinary collaboration, the lab aims to reveal how these proteins function and interact with their surrounding membranes.

Dr. Karen S. Anderson's lab at Yale University focuses on developing new treatments for HIV, particularly in designing and optimizing drugs that target HIV reverse transcriptase, an essential enzyme in the HIV life cycle. The lab combines computational methods with experimental studies to develop novel anti-HIV medications that are effective against drug-resistant strains and reduce the HIV reservoirs in patients. By creating long-acting and combination therapies, they aim to improve patient compliance and overall treatment outcomes for those living with HIV.

The lab led by Assaf Alon at Yale University focuses on understanding the roles of the EXPERA family of proteins in cholesterol and lipid metabolism. These proteins, including the sigma-2 receptor and TM6SF2, are significant in various diseases such as cancer, Alzheimer's, and metabolic disorders. The lab employs structural biology techniques to explore protein interactions and develop therapeutic strategies that could lead to novel treatments.

Dr. Dianqing Wu's research lab at Yale University focuses on understanding the roles of neutrophils and their interaction with polyunsaturated fatty acids (PUFAs) in inflammation and heart health. The lab investigates novel mechanisms of lipid transport and signaling in immune cells, particularly looking at how these processes contribute to diseases like myocardial infarction and cancer. The insights gained aim to uncover potential therapeutic targets for treating inflammatory diseases and enhancing cancer immunotherapy.

Dr. Mark A. Lemmon's lab focuses on understanding unique signaling mechanisms used by unusual receptor tyrosine kinases (RTKs) that play critical roles in various human diseases, including cancer and congenital defects. The research aims to uncover how these receptors, particularly those involved in WNT signaling, can function without the traditional activation methods used by most RTKs. This innovative approach may lead to the discovery of new ways to treat conditions linked to these poorly understood receptors.